^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Endometrial Adenocarcinoma |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
7 - A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma
Published date:
03/28/2020
Excerpt:
Women with recurrent USC were eligible for this study...Patients were required to have had at least 1 prior platinum-based chemotherapy regimen; those with MSI-H/MMRd disease were required to have already received prior therapy with a PD1/PDL1 therapy or to be ineligible for such therapy....Adavosertib monotherapy demonstrated clinical activity in women with USC, with a preliminary response rate of 30%.
